Vaxxa's Q1 2025 saw rapid growth in the insolvency segment, with handled bankruptcies up eightfold and 4.6 MSEK raised via warrants. Despite lower reported revenue due to accounting changes, cash position and market share improved.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.